According to previous studies, IL1B could be a key pro-fibrotic mediator (Park et al., 2018), and IL1B+FCN1hi cells were involved in skin and lung fibrosis, indicating that the cluster might be a new therapeutic target for SSc (Aran et al., 2019). This evidence concerns the gene IL1B and systemic sclerosis.